Move Over, Vial. In a new titra/news/conference-coverage/donanemab-small-tweak-titration-big-gain-safetytion protocol (bottom ...

Eli Lilly has followed through on its plan to file for approval of its Alzheimer's disease candidate donanemab, and is planning to take on Biogen and Eisai with a head-to-head trial against their ...

How effective is it? Manufacturer Eli Lilly found that the drug “significantly” slowed cognitive decline in Alzheimer’s patients in its clinical trials. Donanemab, also known as Kisunla ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

of drugmaker Eli Lilly in Indianapolis, at the annual Clinical Trials on Alzheimer's Disease meeting. The standard dosing ...

And another reason to be optimistic about Eli Lilly might be the approval of Kisunla (the brand name for donanemab). During the previous earnings call, management stated: We achieved several key ...

Eli Lilly (LLY) announced “positive results ... endpoint for people receiving a slightly modified titration of donanemab in adults with early symptomatic Alzheimer’s disease.

How effective is it? Manufacturer Eli Lilly found that the drug “significantly” slowed cognitive decline in Alzheimer’s patients in its clinical trials. Donanemab, also known as Kisunla ...

Lilly said it remains confident in the cost-effectiveness of donanemab and will work closely with NICE during the consultation period, which ends on Nov. 20. Donanemab, given as an infusion every ...

The National Institute for Health and Care Excellence said in draft guidance released Wednesday that the drug, Eli Lilly’s donanemab, “cannot currently be considered good value for the ...

Oct 22 (Reuters) - Britain's National Health Service (NHS) will block Eli Lilly's (LLY.N), opens new tab Alzheimer's drug donanemab on Wednesday, deeming it too expensive for NHS patients ...